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Abstract
Background: The choice of optimal antithrombotic regimen after transcatheter aortic valve replace-
ment (TAVR) remains a matter of debate. The objective of this study was to compare both efficacy and 
safety outcomes based on the type of antithrombotic therapy prescribed after TAVR
Methods: This is a retrospective analysis of 514 consecutive patients treated with either dual antiplate-
let therapy (DAPT) (n = 315; 61.3%) or oral anticoagulation (OAC) plus clopidogrel (n = 199; 38.7%) 
for a minimum of 3 months after TAVR followed by antiplatelet monotherapy or OAC only, respectively. 
Patients had pre-defined clinical and echocardiographic follow-ups at 30 days, 6 and 12 months. The 
key efficacy endpoint was a composite of all-cause death, myocardial infarction, stroke and valve throm-
bosis at 1 year. The key safety endpoint was the occurrence of life-threatening/major bleeding at 1 year.
Results: Baseline characteristics did not differ between both groups, except for a higher incidence of 
atrial fibrillation in the OAC group. No significant differences in both efficacy and safety endpoints were 
observed at 30 days and 6 months. At 1 year, the key efficacy endpoint occurred in 21.5% of the DAPT 
group compared to 19.7% of the OAC group (p = 0.61). The key safety endpoint occurred in 25.1% and 
27.8%, respectively (p = 0.53). However, after 1 year valve thrombosis was reported in 8 (2.5%) patients 
in the DAPT group but not in the OAC group (p = 0.02).
Conclusions: OAC after TAVR seems to reduce the risk of clinical valve thrombosis without a statisti-
cally significant increase in bleeding complications. (Cardiol J 2017; 24, 6: 649–659)
Key words: oral anticoagulation, platelet aggregation inhibitors, transcatheter aortic 
valve replacement, valve thrombosis
Introduction
The use of antithrombotic medication fol-
lowing transcatheter aortic valve replacement 
(TAVR) is currently based on empirical data and 
mainly derived from clinical experience with 
coronary stenting and established surgical valve 
procedures. The risk of thromboembolic events 
after TAVR have been reported to be the highest 
within the first days after intervention, in line with 
the experience gained over the last decades from 
surgical bioprosthetic valves [1–3]. Current multi-
society guidelines recommend a dual antiplatelet 
regimen defined as a combination of low-dose 
aspirin and the thienopyridine clopidogrel for at 
least 3 to 6 months after TAVR [4]. However, data 
supporting this concept are sparse. A recently 
published propensity matched analysis of pooled 
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data from 672 TAVR patients treated with either 
dual antiplatelet therapy (DAPT) or aspirin alone 
suggests that DAPT is associated with higher 
rates of bleeding complications compared to as-
pirin monotherapy, while net adverse ischemic 
and thrombotic events, including stroke, did not 
differ between the groups at 30 days [5]. Patients 
undergoing TAVR with underlying atrial fibrillation 
(AF) or previous thromboembolic events constitute 
a particularly challenging population with regard 
to the post-interventional antithrombotic manage-
ment. AF has been reported in more than 30% of 
the patients considered for TAVR and is associated 
with a markedly increased risk of mortality and 
thromboembolic events after valve replacement 
[6, 7]. In addition, new onset AF was observed in 
one third of the patients undergoing continuous 
electrocardiographic (ECG)-monitoring after TAVR 
and associated with higher rates of postprocedural 
embolic events [8]. Identifying the appropriate 
anticoagulation strategy after TAVR remains an 
important clinical challenge that has resulted in 
a large variability of antithrombotic therapies, rang-
ing from triple therapy (DAPT + oral anticoagulation 
[OAC]) to vitamin-K antagonists (VKA) alone [9]. 
Finally, recent reports on low but clinically rele-
vant incidence of valve thrombosis hindering 
prosthesis function may further lead to an up-
heaval in the landscape of thrombotic therapy after 
TAVR [10–12].
The objective of the present retrospective 
single center registry analysis was to compare the 
safety and efficacy outcomes for up to 1 year of 
either an antiplatelet therapy or OAC after TAVR.
Methods
Study design
This retrospective analysis was performed in 
a single-center prospective cohort study aiming for 
consecutive enrolment of all patients undergoing 
TAVR procedures at the Heart Center Segeberger 
Kliniken, Bad Segeberg, Germany. Data collection 
was approved by the local ethics committee and 
informed written consent was obtained from all 
patients. The current analysis includes 514 con-
secutive patients who underwent TAVR between 
September 2007 and December 2014 at the Heart 
Center Segeberger Kliniken, Germany. Twenty 
patients were excluded from this analysis because 
of antithrombotic treatments other than DAPT or 
OAC, or due to procedure related death (Fig. 1). 
Procedure
Transcatheter aortic valve replacement was 
performed in all patients with Conformité Euro-
péenne marked devices. TAVR procedures were 
conducted via trans-femoral, trans-subclavian, 
trans-apical or trans-aortic access sites. Device 
success was defined according to the Valve Aca-
demic Research Consortium 2 (VARC-2) consensus 
document, which is a technical composite end point 
including successful vascular access, delivery and 
deployment of the device and successful retrieval 
of the delivery system; correct position of the 
device in the proper anatomical location; intended 
performance of the prosthetic heart valve (aortic 
valve area [AVA] > 1.2 cm2, mean aortic valve 
gradient < 20 mm Hg, or peak velocity < 3 m/s, 
Figure 1. Study design and patient enrolment; DAPT — dual antiplatelet therapy; OAC — oral anticoagulation.
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without moderate or severe prosthetic valve aortic 
regurgitation as assessed by post-interventional 
transthoracic echocardiography [TTE]) and having 
only 1 valve implanted in the proper anatomical 
location [13, 14].
Antithrombotic regimen following TAVR
Patients were categorized into two groups 
based on the antithrombotic therapy established 
after TAVR. The DAPT group consisted of 315 
(61.3%) patients treated with a combination of oral 
aspirin and clopidogrel for 3 months followed by 
lifelong aspirin therapy. The OAC group included 
199 (38.7%) patients treated with a combination 
of an OAC + clopidogrel for 3 months followed by 
OAC alone (Fig. 1). In patients treated with con-
comitant percutaneous coronary intervention (PCI) 
and drug-eluting stent implantation antithrombotic 
therapy with DAPT or combination of OAC + clo-
pidogrel was pursued for up to 6 months.
Follow-up and study endpoints
All patients in the registry had a pre-defined 
clinical and transthoracic echocardiographic (Vivid 
7 Ultrasound Machine and a M4S matrix array 
sector transducer GE Medical Systems, Milwau-
kee, WI, USA) follow-up at 30 days, 6 months and 
1 year. Additional transesophageal echocardiogra-
phy (TEE) evaluation was performed in cases of 
worsening symptoms or suspected valve throm-
bosis, defined as valve dysfunction (mean trans-
valvular gradient > 20 mm Hg, reduction of the 
AVA to < 1.2 cm2 or new onset more than mild 
transvalvular regurgitation) or newly apparent 
mobile mass suspicious of thrombus, irrespective 
of dysfunction, and in the absence of infection. 
In addition, multidetector computed tomography 
(MDCT) examination was performed to further 
confirm the diagnosis of suspected valve throm-
bosis. CT examination was done with a second 
generation dual-source CT scanner (Somatom 
Definition Flash, Siemens Healthcare, Forchheim, 
Germany). Contrast enhanced ECG-gated acquisi-
tion of the aortic root was performed after injection 
of iodinated contrast agent with the region of inter-
est placed in the ascending aorta and axial sections 
of 0.6 mm. All data were transferred to a dedicated 
post-processing workstation (Syngo Multimodal-
ity Workplace, Siemens Healthcare, Forchheim, 
Germany) for analysis. Images were evaluated for 
hypoattenuating areas with or without reduced 
mobility of one or more leaflets identifiable in two 
different projections. Valve thrombosis was clas-
sified based on the timing of diagnosis after TAVR 
as acute (0–10 days); subacute (11–30 days) or late 
(> 1 month). Pre-specified efficacy endpoints of 
this study were defined as all-cause death, myo-
cardial infarction (MI), stroke and clinical valve 
thrombosis at 30 days, 6 months and 1 year. The 
key efficacy endpoint was a composite of all at 
1 year. The key safety endpoint was the occurrence 
of life threatening or major bleeding at 1 year. In-
dividual endpoints were defined according to the 
VARC-2 criteria for event definition [14].
Statistical analysis
Continuous data are reported as mean 
± standard deviation (SD) for normally distributed 
variables and as median with interquartile range 
(IQR) for non-normally distributed variables. 
Categorical variables are reported as number 
of patients (% of patients). Normally and non-
normally distributed variables were compared 
using the Student’s t-test or the Mann-Whitney 
U test accordingly. Comparisons between cat-
egorical variables were performed using the 
c2 or Fisher’s exact test, wherever appropriate. 
In order to identify whether the anti-thrombotic 
treatment strategy was predictive of all-cause 
mortality, cardiovascular mortality, stroke, major 
bleeding, or combined efficacy and safety end-
points multivariable binary logistic regression 
analysis was performed. Variables which reached 
a p-value < 0.1 on univariate binary regression 
analysis were included in the model. Variables 
are adjusted for age, sex, body mass index (BMI), 
AF and staged PCI. All tests were two-tailed and 
a p-value of < 0.05 was considered as statistically 
significant. All the analyses were retrospective 
and performed using STATA version 14 (STATA 
Corp., TX, USA) or SPSS (SPSS, Release 22; 
SPSS Inc, Chicago, IL). 
Results
A total of 514 consecutive patients that un-
derwent TAVR at the indicated institution were 
included in this study. The mean age of the study 
population was 80.4 years, 43.7% were males, 
with a median logistic EuroScore of 18.49%. In 
both groups patients had severe aortic stenosis. 
Echocardiographic characteristics did not differ 
significantly in either group. The mean (± SD) 
gradient was 46 ± 16.8 mm Hg in the DAPT 
group and 44 ± 16.8 mm Hg in the OAC group 
(p = 0.27). The indexed AVA was 0.41 ± 0.2 
cm2/m2 and 0.39 ± 0.2 cm2/m2 (p = 0.28). The 
two groups had similar baseline characteristics 
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(Table 1), except for a higher incidence of AF in 
the OAC group (10.5% vs. 69.2%; p < 0.01) and 
a higher rate of staged PCI in patients undergo-
ing TAVR in the DAPT group (40.1% vs. 28.3%; 
p = 0.01). Procedural characteristics did not dif-
fer between either group (Table 2). At discharge, 
315 (61.3%) patients received DAPT and 199 
(38.7%) a combination of OAC and clopidogrel 
(n = 188 phenoprocoumon, n = 7 rivaroxaban, 
n = 4 dabigatran) following TAVR (Fig. 1). 
Outcomes at 30 days
At 30 days, all-cause mortality occurred in 
a total of 18 (3.5%) patients, 11 (3.5%) in the DAPT 
group and 7 (3.5%) in the OAC group (p = 0.98) 
(Table 3). Cardiovascular mortality was reported in 
Table 1. Baseline characteristics of the study population.
DAPT (n = 315) OAC (n = 199) P
Age [years], mean ± SD 80.4 ± 7.0 80.6 ± 5.7 0.73
Female 181 (57.6%) 107 (54%) 0.43
Body mass index, mean ± SD 26.4 ± 4.9 27.5 ± 4.8 < 0.01
Diabetes mellitus 81 (25.8%) 59 (29.8%) 0.32
Hypertension 279 (88.8%) 172 (86.9%) 0.49
Hyperlipidemia 179 (57%) 116 (58.6%) 0.72
Atrial fibrillation 33 (10.5%) 137 (69.2%) < 0.01
Previous stroke 35 (11.1%) 24 (12.1%) 0.23
CHA2DS2-VASc-score, mean ± SD 4.8 ± 1.33 4.6 ± 1.33 0.47
Coronary artery disease 215 (68.5%) 126 (63.6%) 0.25
Staged PCI 126 (40.1%) 56 (28.3%) < 0.01
Previous CABG 64 (20.4%) 31 (15.6%) 0.18
Carotid artery disease 44 (14%) 22 (11.1%) 0.34
Peripheral vascular disease 46 (14.6%) 32 (16.2%) 0.64
EuroScore Logistic, median (IQR) 18.5 (11.4–29.9) 18.2 (12.5–31.0) 0.92
DAPT — dual antiplatelet therapy; OAC — oral anticoagulation; SD — standard deviation, PCI — percutaneous coronary intervention;  
CABG — coronary artery bypass graft; IQR — interquartile range
Table 2. Procedural characteristics.
DAPT (n = 315) OAC (n = 199) P
Access route:
Transfemoral 308 (97.8%) 195 (98.0%) 1.0
Transapical 2 (0.6%) 3 (1.5%) 0.38
Subclavian 3 (0.9%) 0 (0.0%) 0.28
Transaortic 2 (0.6%) 1 (0.5%) 1.0
Self-expandable valve prosthesis 183 (58.1%) 104 (52.3%) 0.20
Balloon-expandable valve prosthesis, 115 (36.5%) 79 (39.7%) 0.51
Lotus valve prosthesis 17 (5.4%) 16 (8.0%) 0.27
Device success 268 (85.1%) 174 (87.4%) 0.51
Valve-in-valve procedure 14 (4.4%) 11 (5.5%) 0.67
Periinterventional vascular complications:
Minor 16 (5.1%) 9 (4.5%) 0.83
Major 14 (4.4%) 16 (8.1%) 0.12
DAPT — dual antiplatelet therapy; OAC — oral anticoagulation
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3.5% of the patients in the DAPT group and 2.5% in 
the OAC group (p = 0.61). There was no significant 
difference between either group in the incidence 
of MI (0.9% vs. 0.5%, p = 1.0), stroke (3.8% vs. 
3.5%, p = 0.86) or valve thrombosis (0.3% vs. 0%, 
p = 1.0) at 30-days. Also safety endpoints did not 
differ between either group: life-threatening bleed-
ing (7.3% vs. 9.5%, p = 0.36) and major bleeding 
(16.8% vs. 15.1%, p = 0.60). 
Outcomes at 6 months
At 6 months, all-cause mortality was reported 
in 25 (7.9%) patients in the DAPT group and 24 
(12.1%) patients in the OAC group (p = 0.15) 
(Table 4). There was no significant difference 
between DAPT and OAC groups in the incidence 
of MI (1.6% vs. 0.5%, p = 0.41) and stroke (4.5% 
vs. 4.1%, p = 0.83). Although valve thrombosis 
was only reported in the DAPT group, there was 
no statistically significant difference (1.9% vs. 
0%, p = 0.08) between the groups after 6 months. 
Combined efficacy (15.3% vs. 14.6%, p = 0.8) and 
safety (24.4% vs. 26.1%, p = 0.64) endpoints at 
6 months did not differ significantly (Table 4).
Safety and efficacy endpoints at 1 year
At 1 year all-cause mortality had occurred in 
a total of 74 (14.4%) patients. 39 (12.4%) deaths were 
reported in the DAPT group and 35 (17.6 %) in the 
OAC group (Fig. 2). Even though a trend towards 
a higher mortality rate could be observed in the 
OAC group, this increase did not reach statistical 
significance (p = 0.09). Furthermore, there was 
no difference in MI (2.9% vs. 0.5%, p = 0.09) and 
stroke (5.2% vs. 4.1%, p = 0.67) rates between 
the DAPT and OAC groups. After 1 year, 8 (2.5%) 
cases of valve thrombosis were documented in the 
group of patients on antiplatelet treatment, while in 
patients on OAC no valve thrombosis was reported 
(2.5% vs. 0%, p = 0.02). Combined key efficacy 
(21.5% vs. 19.7%, p = 0.61) and safety (25.1% vs. 
27.8%, p = 0.53) endpoints at 1 year did not differ 
between the groups (Fig. 3). An adjusted logistic 
regression analysis confirmed that despite a trend 
Table 3. Outcomes at 30 days.
DAPT (n = 315) OAC (n = 199) P
All cause death 11 (3.5%) 7 (3.5%) 0.98
Cardiovascular death 11 (3.5%) 5 (2.5%) 0.61
Myocardial infarction 3 (0.9%) 1 (0.5%) 1.0
Stroke, all 12 (3.8%) 7 (3.5%) 0.86
Transcatheter heart valve thrombosis 1 (0.3%) 0 (0%) 1.0
Combined efficacy endpoint 26 (8.2%) 13 (6.5%) 0.47
Life threatening bleeding 23 (7.3%) 19 (9.6%) 0.36
Major bleeding 53 (16.8%) 30 (15.1%) 0.60
Combined safety endpoint 76 (24.1%) 49 (24.6%) 0.88
DAPT — dual antiplatelet therapy; OAC — oral anticoagulation
Table 4. Outcomes at 6 months.
DAPT (n = 315) OAC (n = 199) P
All cause death 25 (7.9%) 24 (12.0%) 0.15
Cardiovascular death 16 (5.0%) 14 ( 7.0%) 0.12
Myocardial infarction 5 (1.6%) 1 (0.5%) 0.41
Stroke, all 14 (4.4%) 8 (4.0%) 0.83
Transcatheter heart valve thrombosis 6 (1.9%) 0 (0%) 0.08
Combined efficacy endpoint 48 (15.2%) 29 (14,6%) 0.86
Major bleeding 55 (17.5%) 33 (16.5%) 0.80
Combined safety endpoint 76 (24.1%) 51 (25.6%) 0.64
DAPT — dual antiplatelet therapy; OAC — oral anticoagulation
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towards an increase in all-cause mortality after 
1 year observed in patients under OAC there was 
no overall statistically significant difference in 
the occurrence rates of the predefined endpoints 
(Fig. 3). However, OAC reduced the risk of valve 
thrombosis independent of age, sex, BMI, AF and 
whether staged PCI was performed (OR 0.53; 95% 
CI 0.23–0.76).
Clinical features of transcatheter  
heart valve thrombosis
In the current analysis transcatheter heart 
valve (THV) thrombosis was reported in 8 patients 
with a mean age of 78.7 years. Median and mean 
time to diagnosis of THV thrombosis were 181 
(IQR 176–263) days and 196 days, respectively. 
THV thrombosis was considered to be subacute 
in 1 and late in 7 patients (Table 5). All 8 cases 
of THV thrombosis occurred in the DAPT group. 
While 2 patients were still under DAPT (aspirin/ 
/clopidogrel) 6 patients were under aspirin mono-
therapy at the point in time of diagnosis of THV 
thrombosis. Cases of valve thrombosis included 
7 patients who had undergone TAVR with a balloon 
expandable THV and 1 patient treated with a self-
expandable THV. Three cases of THV thrombosis 
Figure 3. Adjusted interaction between dual antiplatelet therapy (DAPT) or oral anticoagulation (OAC) after transcath-
eter aortic valve replacement on outcomes at one year. Variables are adjusted for age, sex, body mass index, atrial 
fibrillation and staged percutaneous coronary intervention. Odds ratios are displayed with 95% confidence interval 
on a logarithmic scale; THV — transcatheter heart valve.
Figure 2. Summary of defined endpoints and outcomes at 1 year in the dual antiplatelet therapy (DAPT) and oral 
anticoagulation (OAC) group; CEE — combined efficacy endpoint; CSE — combined safety endpoint; CV — cardio-
vascular.
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occurred in patients who underwent TAVR for 
treatment of degenerated surgical bioprosthesis 
(valve-in-valve). Worsening dyspnea was the lead-
ing clinical manifestation of THV thrombosis and 
was observed in 5 patients. In the other 3 patients 
no clinical symptom could be attributed to the oc-
currence of THV thrombosis. No case of stroke, MI 
or peripheral embolism could be associated to THV 
thrombosis. Elevated transvalvular gradients was 
the leading finding in all patients on TTE exami-
nation. The peak and mean transaortic gradients 
at the time of diagnosis of THV thrombosis were 
61 mm Hg and 39 mm Hg, respectively. TEE was 
performed in all patients with suspected THV 
thrombosis. TEE findings included restricted leaf-
let mobility (n = 3), thrombotic mass (n = 3) and 
thickened leaflets (n = 4) (Table 5). In 1 case TEE 
was inconclusive. CT examination was performed 
in 4 patients and demonstrated hypoattenuated 
lesions of the leaflets and restricted leaflet mo-
tion consistent with THV thrombosis. All patients 
diagnosed with THV thrombosis were treated 
with VKA in therapeutic doses. Three patients 
were treated in addition with clopidogrel. Under 
OAC follow-up TTE examinations documented 
a decrease of the transvalvular gradients in all pa-
tients. Follow up CT was performed in 3 patients 
1 (n = 2) and 2 (n = 1) months after initiation of 
anticoagulant therapy confirmed resolution of the 
hypoattenuated lesions and leaflet thickening with 
restoration of leaflet motion. After resolution of 
THV thrombosis OAC was ceased in 3 patients 
while VKA treatment was continued in 5 patients. 
No recurrence of THV thrombosis was reported.
Modification of therapeutic regimen
During the observational period of 1 year, 
37 patients underwent modification of their thera-
peutic regimen. 19 patients of the DAPT group 
switched to OAC and 18 patients of the OAC group 
switched to DAPT due to clinical indications. 
Follow-up classification and statistical analysis was 
based on an intention-to-treat analysis.
Discussion
This retrospective analysis of a single center 
registry compared outcomes of two antithrombotic 
regimen following TAVR. After a follow-up period 
of 1 year no significant differences in predefined 
cumulative efficacy and safety endpoints were ob-
served between an antithrombotic strategy based 
on early phase DAPT for 3–6 months according 
to current guideline recommendations and OAC. 
However, clinical valve thrombosis after TAVR 
occurred only in the DAPT group and was success-
fully treated by the establishment of OAC.
Most cardioembolic events after TAVR were 
reported to occur within the first days after TAVR 
[15]. In the present study, the incidence of all-cause 
mortality, stroke and MI at 30 days was comparable 
to results previously published in prospective land-
mark trials as well as nationwide registries [16–20]. 
Post interventional DAPT or OAC resulted in 
similar rates of MI, stroke and all-cause mortality 
up to 6 months after TAVR thereby underscoring 
the efficacy of both therapeutic regimens. After 
6 months, patients in the DAPT group were placed 
on single antiplatelet therapy (aspirin) while anti-
coagulation was pursued in the OAC group due to 
comorbidities, in particular paroxysmal or perma-
nent AF. One year after TAVR, aspirin monotherapy 
also yielded similar results as compared to OAC 
regarding predefined efficacy endpoints. Hence, the 
present results are in line with previous studies 
strongly supporting an interruption of DAPT after 
a period of 3–6 months in TAVR patients who do 
not have any further indication for DAPT such as 
recent acute coronary syndrome (< 12 months) or 
coronary stent implantation (< 6 months) [5, 21, 
22]. Interestingly, after 1 year, and despite adjust-
ment for the occurrence of AF and other variables, 
a trend towards an increased all-cause mortality in 
the OAC group could be observed. Considering the 
limited size of the study population as well as the 
retrospective nature of the study, this observation 
requires careful interpretation.
In the relatively young era of percutaneous 
aortic valve replacement, an increasing number of 
reports has emerged describing cases of clinically 
relevant subacute post-TAVR valve thrombosis 
and recently identified reduced leaflet motion in 
MDCT, which may correspond to a subclinical sur-
rogate of valve thrombosis [10, 11, 23–25]. These 
reports about post-TAVR valve thrombosis and 
hindered leaflet function have generated debate 
about the clinical relevance of this phenomenon. In 
the present study, valve thrombosis was diagnosed 
based on routine echocardiographic follow-up 
examination in 1.5% of the total population and 
as often as 2.5% in patients initially treated with 
DAPT. Diagnosis was based on echocardiographic 
parameters demonstrating a significant increase 
in transvalvular pressure gradients or thrombotic 
mass and confirmed by MDCT findings reporting 
thickening of the leaflets and reduced leaflet mo-
tion. THV thrombosis manifested as worsening 
of dyspnoea in 5 of 8 patients while it was not as-
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sociated to any clinical symptoms in 3 patients. In 
patients diagnosed with THV thrombosis, DAPT 
was replaced by OAC for at least 3 months and 
follow-up intervals were shortened. Follow-up 
echocardiography as well as clinical examination 
documented restoration of valve function under 
OAC by decreases of peak and mean transvalvu-
lar gradients over valve prosthesis, resolution of 
thrombotic mass as well as improvement of clinical 
symptoms in all patients. Interestingly, in contrast 
to the DAPT group, no cases of valve thrombosis 
were diagnosed in any of the patients on OAC and 
logistic regression analysis demonstrated that 
OAC was associated with a significantly lower risk 
of developing THV thrombosis. This observation 
is in line with current reports in the literature 
suggesting that OAC but not antiplatelet therapy 
prevents valve thrombosis [26–28]. Further stud-
ies are required in order to better characterize 
this subgroup of patients and to identify potential 
predictors which reveal those patients who may 
benefit from OAC after TAVR apart from other 
indications for anticoagulant therapy. 
Hemorrhagic complications are frequent, and 
major or life-threatening bleeding after TAVR oc-
cur in 20–30% and 15%, respectively [16, 17, 29]. 
Regardless of the underlying mechanisms, disa-
bling or life-threatening bleeding is an important 
predictor of acute and late mortality in patients 
undergoing TAVR. Predictors of bleeding com-
plications have been identified by several groups 
[30, 31]. Among them, vascular or major intrap-
rocedural complications, female sex, and base-
line anemia have been most frequently reported. 
While periprocedural bleeding is driven mainly by 
anatomical and technical considerations, major and 
life-threatening bleeding occurring at later points 
in time appear to be related mainly to patient bleed-
ing susceptibility, triggered by the antithrombotic 
agent used. In the current analysis the composite 
safety endpoint occurred mainly within the first 
6 months after TAVR in both groups. This observa-
tion strongly suggests that both DAPT and the 
combination of OAC with a single antiplatelet drug 
such as clopidogrel results in a significant increase 
of hemorrhagic complications after TAVR in a pa-
tient population that is at particular high risk for 
bleeding due to comorbidities and frailty. At 1 year 
the incidence of the composite safety endpoint was 
only slightly higher in both groups as compared to 
the 6 months time point and was mostly related to 
the fact that after a maximum of 6 months thieno-
pyridine therapy was ceased in patients without an 
indication for further long-term clopidogrel treat-
ment such as acute coronary syndrome. Previous 
studies and registries have reported a short-term 
hazard related to bleeding complications that 
were most apparent during the first 3 months of 
initiation of either VKA plus a single antiplatelet 
drug or DAPT treatment [32, 33]. A most recent 
meta-analysis excluding patients on OAC demon-
strated that aspirin monotherapy while being as 
efficient as DAPT in preventing post-interventional 
thromboembolic complications and was superior to 
DAPT with regard to bleeding complications [5]. 
Taken together these observations may challenge 
the current practice recommending DAPT for 
3–6 months after TAVR but these results need 
to be confirmed by currently ongoing prospective 
randomized trials. With regard to the management 
of antithrombotic therapy after TAVR in patients 
on OAC, further data reporting is warranted. In 
this retrospective analysis patients on OAC were 
treated with clopidogrel for at least 3 months after 
TAVR according to current recommendations [4]. 
Since the majority of the bleeding events oc-
curred in this group within the first 6 months, the 
net benefit of adding a platelet inhibitor on top of 
OAC may be questioned. As for DAPT, prospective 
randomized trials are required to define the most 
appropriate antithrombotic post-TAVR therapy in 
patients on OAC. Finally, while the newer direct 
oral anticoagulants have proven to be safer and 
at least as efficient as VKA in the prevention of 
thromboembolic events in patients with underlying 
non-valvular AF, their role in patients undergoing 
TAVR remains to be defined.
Limitations of the study
As for every retrospective cohort analysis 
limitations such as patient and treatment selec-
tion biases need to be considered. The reporting 
in this study followed the VARC-2 criteria and was 
predefined. TEE and MDCT examinations were 
only performed in patients with suspected valve 
thrombosis defined by worsening transvalvular 
gradient on follow-up TTE or new onset of symp-
toms. Hence, it seems likely that the incidence of 
subclinical valve thrombosis which may be more 
accurately diagnosed by routine MDCT or TEE 
examination may have been underestimated in this 
retrospective study. 
Conclusions
This single center analysis suggests that 
DAPT and OAC are associated with similar clini-
cal outcomes at 1 year with regard to predefined 
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safety and efficacy endpoints in patients undergoing 
TAVR. In addition, OAC seems to reduce the risk 
of clinical valve thrombosis without a significant 
increase in major bleeding complications. Further 
randomized controlled trials assessing the optimal 
antithrombotic therapy after TAVR are both justi-
fied and needed.
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